• Data to be Presented on Key Pipeline Products: MitraClip® System and Absorb™ Bioresorbable Vascular Scaffold
• Company's XIENCE Family of Drug Eluting Stents Continues to Lead the Market, Supported by Strong Clinical Data

Abbott Park, Illinois  — Abbott today announced the company's schedule of key presentations at the American College of Cardiology's (ACC) 61st Annual Scientific Session and i2  Summit 2012, to be held March 24 – 27 in Chicago. Presentations will include the following: data on patients at high surgical risk treated with the investigational MitraClip® system, an innovative catheter-based device for mitral valve repair; and two-year clinical results on the investigational Absorb™ bioresorbable vascular scaffold (BVS), a novel device designed to restore blood flow to the heart and then dissolve, leaving the patient with a vessel free of a permanent metallic implant. In addition, there will be a number of presentations on Abbott's XIENCE V® Everolimus Eluting Coronary Stent System as well as preliminary results from a unique pilot program that screens women for cardiovascular risk factors at obstetrics/gynecology clinics.

"Abbott has achieved worldwide vascular leadership by developing innovative products to advance patient care, such as the XIENCE family of drug eluting stents. XIENCE is the world's leading drug eluting stent and continues to gain market share in the U.S. and internationally – supported by a consistent stent design and solid clinical data from more than 100 clinical trials," said Robert B. Hance, senior vice president, vascular, Abbott. "We continue to strengthen our leadership position with first-of-their-kind technologies such as the MitraClip system and the Absorb bioresorbable vascular scaffold – two devices with the potential to have a significant impact on patient care. We look forward to presenting new data for these important technologies at the upcoming ACC meeting."

Key MitraClip system presentations are as follows (all times are Central):

• Survival in Patients with Moderate to Severe Mitral Regurgitation at High Risk for Surgery Treated with and without the MitraClip: A Propensity Matched Comparison − Sunday, March 25, from 9:30 a.m. to 10:30 a.m. in Hall A of McCormick Place South.
• EVEREST II High-Risk Cohort: Baseline Characteristics and One-Year Outcomes in Men vs. Women − Sunday, March 25, from 9:30 a.m. to 10:30 a.m. in Hall A of McCormick Place South.
• ACCESS EUROPE: A Post-Market Study of the MitraClip System for the Treatment of Significant Mitral Regurgitation in Europe: Analysis of Outcomes at Six Months − Sunday, March 25, from 10:45 a.m. to 11 a.m. in Room N427 of McCormick Place North.
• The Relationship Between the Magnitude of Reduction in Mitral Regurgitation Severity and Left Ventricular and Left Atrial Volumes Post-Treatment with the MitraClip Device − Sunday, March 25, from 11 a.m. to 11:15 a.m. in Room N427 of McCormick Place North.

In the United States, the MitraClip system is limited to investigational use only and is not available for sale. The MitraClip system is currently under review for approval by the U.S. Food and Drug Administration. The MitraClip system received CE Mark in 2008 and is authorized for sale in Europe and other international markets.

Key Absorb Bioresorbable Vascular Scaffold presentations are as follows (all times are Central):

• Evaluation of the Absorb BVS in the Treatment of Patients with de novo Native Coronary Artery Lesions: Two-Year Clinical Results of the ABSORB Cohort B Trial − Sunday, March 25, from noon to 12:10 p.m. in Room S106b of McCormick Place South.
• First Sequential Assessment at Six Months and Two Years of the Second Generation Absorb Everolimus-Eluting Bioresorbable Scaffold: A Multi-Imaging Modality Study − Sunday, March 25, from 11:25 a.m. to 11:35 a.m. in Room S106b of McCormick Place South.
• Vascular Response of the Segments Adjacent to the Proximal and Distal Edges of the Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold: Six Months and One Year Follow-Up Assessment − Sunday, March 25, from 11:45 a.m. to 11:55 a.m. in Room S106b of McCormick Place South.

In the United States, Absorb is an investigational device and is not available for sale. Absorb has CE Mark and is authorized for sale in Europe.

Women's Heart Health Initiative: Preliminary results from a novel pilot program to screen women for cardiovascular risk factors in obstetrics and gynecology clinics will be presented on Sunday, March 25, from 11 a.m. to noon in Hall A of McCormick Place South. The pilot program, supported by Abbott's Women's Heart Health Initiative (WHHI) in partnership with the Society for Cardiovascular Angiography and Interventions (SCAI) – Women in Innovations program, is designed to address the referral gap between obstetrician/gynecologists and cardiologists, with the goal of early detection of heart disease in women.

Source: Abbott